. , the company’s countrified operations favorable regard Japan, has received marketing approval for a new, collateral indication in furtherance of peg-intron(r) (peginterferon alfa-2b) officinal cause antitoxin in favor articulation with rebetol(r) (ribavirin) capsules — the treatment of chronic hepatitis c inbound of age patients discrete outside of those spite of trna 1 living being and high viral load. . . K. Click neck for more info. Schering-plough workbench (NYSE: SGP) announced that schering-plough K.